These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 19268437

  • 1. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
    Rozenfeld PA, De Francesco NP, Borrajo GJ, Ceci R, Fossati CA.
    Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
    [Abstract] [Full Text] [Related]

  • 2. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry.
    Kitagawa T, Ishige N, Suzuki K, Owada M, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Mills K, Winchester B, Keutzer J.
    Mol Genet Metab; 2005 Jul; 85(3):196-202. PubMed ID: 15979031
    [Abstract] [Full Text] [Related]

  • 3. Determination of globotriaosylceramide in plasma and urine by mass spectrometry.
    Krüger R, Bruns K, Grünhage S, Rossmann H, Reinke J, Beck M, Lackner KJ.
    Clin Chem Lab Med; 2010 Feb; 48(2):189-98. PubMed ID: 19958207
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
    Abaoui M, Boutin M, Lavoie P, Auray-Blais C.
    Clin Chim Acta; 2016 Jan 15; 452():191-8. PubMed ID: 26593248
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fabry disease: perspectives of urinary proteomics.
    Cuccurullo M, Beneduci A, Anand S, Mignani R, Cianciaruso B, Bachi A, Capasso G.
    J Nephrol; 2010 Jan 15; 23 Suppl 16():S199-212. PubMed ID: 21170881
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Is globotriaosylceramide a useful biomarker in Fabry disease?
    Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, Winchester B.
    Acta Paediatr Suppl; 2005 Mar 15; 94(447):51-4; discussion 37-8. PubMed ID: 15895713
    [Abstract] [Full Text] [Related]

  • 18. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
    Manwaring V, Boutin M, Auray-Blais C.
    Anal Chem; 2013 Oct 01; 85(19):9039-48. PubMed ID: 23968398
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
    Auray-Blais C, Blais CM, Ramaswami U, Boutin M, Germain DP, Dyack S, Bodamer O, Pintos-Morell G, Clarke JT, Bichet DG, Warnock DG, Echevarria L, West ML, Lavoie P.
    Clin Chim Acta; 2015 Jan 01; 438():195-204. PubMed ID: 25149322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.